• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 16.48
  • VXN 19.83
  • VXO 17.26
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
VNDA (Vanda Pharmaceuticals Inc.)
Last Trade 17.59 Dividend/Share 0 PE Ratio 37.43
Date March 22-2019 Dividend Yield 0.000 Return on Assets 9.38
Change -0.85 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS 0.48 Price/Sale 4.879
Ask 0 LatestEPS Date 2018-12-31 Price to Book 3.42
Volume 31683 EPS ttm 0.470 Institutional % 152.7
Avg Volume 1.2M Shares Outstanding 52.64M Insider % 4.3
Open 18.34 Float 50.39M Short Ratio null
Prev Close 18.44 Return On Equity 12.39 5 Year Change % 0.027
High 18.34 Consensus EPS -0.03 2 Year Change % 0.261
Low 17.55 No. of Estimate 2.000 1 Year Change % 0.038
52 Week High 33.44 EPS Surprise $ null YTD Change % -0.349
52 Week Low 13.875 EPS Surprise Percent 733.3333 6 Month Change % -0.140
52 Week Change 8.791 EBITDA 0M 3 Month Change % -0.260
50 Day MA 22.8486 Revenue 0M 1 Month Change % -0.154
200 Day MA Gross Profit 0M 5 Day Change % -0.035
Market Cap 970.73M Cash 0M 30 Day Change % -0.072
Beta 0.487819 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
12
Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of clinical-stage products for various central nervous system disorders. Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is developing Tasimelteon, which is in the orphan designation status for the treatment of non-24 hour sleep/wake disorder in blind individuals without light perception. It is also developing Tasimelteon in Phase II trials for the treatment of depression. The company was incorporated in 2002 and is headquartered in Rockville, Maryland.